Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amur Minerals ( (GB:CRTX) ) has provided an update.
CRISM Therapeutics has secured a Japanese patent for its lead product ChemoSeed, covering both the manufacturing processes and therapeutic use of irinotecan-based biodegradable chemotherapeutic implants, particularly for treating brain tumours such as glioblastoma. Management describes Japan as a key market and sees the patent as strengthening the company’s intellectual property portfolio and appeal to potential commercial partners, reinforcing its positioning ahead of a planned registration-grade Phase 2 clinical trial of irinotecan-ChemoSeed in surgically resectable glioblastoma patients in early 2026.
The most recent analyst rating on (GB:CRTX) stock is a Sell with a £9.50 price target. To see the full list of analyst forecasts on Amur Minerals stock, see the GB:CRTX Stock Forecast page.
Spark’s Take on GB:CRTX Stock
According to Spark, TipRanks’ AI Analyst, GB:CRTX is a Neutral.
The score is primarily held back by weak financial performance (minimal revenue, ongoing losses, and negative operating/free cash flow) despite improvement year over year. Technicals are also soft with the stock trading below key longer-term moving averages and a negative MACD. Valuation is difficult to support with a negative P/E and no dividend yield provided.
To see Spark’s full report on GB:CRTX stock, click here.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based, clinical-stage drug delivery company specialising in innovative localised and sustained delivery of chemotherapy for solid tumours. Its lead product, ChemoSeed, is an implantable biodegradable device designed to deliver chemotherapeutic agents such as irinotecan directly into tumours or resection margins, including in glioblastoma, helping to bypass barriers like the blood-brain barrier and improve treatment efficacy.
Average Trading Volume: 136,404
Technical Sentiment Signal: Sell
Current Market Cap: £5.17M
Find detailed analytics on CRTX stock on TipRanks’ Stock Analysis page.